Literature DB >> 15538630

Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease.

Christiane Mühle1, Qiu-Jie Jiang, Alexandra Charlesworth, Leena Bruckner-Tuderman, Guerrino Meneguzzi, Holm Schneider.   

Abstract

Herlitz disease (H-JEB), the lethal form of junctional epidermolysis bullosa, is a rare genodermatosis presenting from birth with widespread erosions and blistering of skin and mucosae because of tissue cleavage within the epidermal basement membrane. Mutations in any of the three genes encoding the alpha3, beta3 and gamma2 chains of laminin-5 underlie this recessively inherited disorder. Here, we report the molecular basis and clinical course of H-JEB in 12 patients. Two novel nonsense mutations in the gene LAMA3 (E281X and K1299X) and a novel frame-shift mutation in the gene LAMB3 (1628insG) leading to a premature termination codon were identified by DNA sequencing and confirmed by restriction fragment length polymorphism analysis. In the four patients affected, neither the resulting truncated polypeptide chains nor assembled laminin-5 protein were detectable by immunofluorescence. Three patients were found to be heterozygous for the known hotspot mutation R635X and the recurrent mutations Q373X or 29insC in the gene LAMB3, whereas five others were homozygous for R635X. Significant variations in the disease progression and survival times between 1 and 30 months in this group of H-JEB patients emphasised the impact of modifying factors and the importance of immunostaining or mRNA assessment as parallel diagnostic methods. Interestingly, the only patients who survived for longer than 6 months were four females carrying the mutation R635X homozygously. In one of them, the clinical course may have been improved by treatment with artificial skin equivalents. These data may stimulate further investigation of genotype-phenotype correlations and facilitate mutation analysis and genetic counselling of affected families.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538630     DOI: 10.1007/s00439-004-1210-y

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  49 in total

1.  Isolation and activity of proteolytic fragment of laminin-5 alpha3 chain.

Authors:  Y Tsubota; H Mizushima; T Hirosaki; S Higashi; H Yasumitsu; K Miyazaki
Journal:  Biochem Biophys Res Commun       Date:  2000-11-30       Impact factor: 3.575

Review 2.  Epidermolysis bullosa: scientific advances and therapeutic challenges.

Authors:  R A Eady
Journal:  J Dermatol       Date:  2001-11       Impact factor: 4.005

3.  Differential expression of laminin alpha chains during proliferative and differentiation stages in a model for skin morphogenesis.

Authors:  R Fleischmajer; K Kuroda; A Utani; E Douglas MacDonald; J S Perlish; E Arikawa-Hirasawa; K Sekiguchi; N Sanzen; R Timpl; Y Yamada
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

4.  Detection of sequence variants in the gene encoding the beta 3 chain of laminin 5 (LAMB3).

Authors:  L Pulkkinen; J A McGrath; A M Christiano; J Uitto
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

5.  Hematopoietic stem cell transplantation and subsequent 80% skin exchange by grafts from the same donor in a patient with Herlitz disease.

Authors:  Jürgen Kopp; Raimund E Horch; Klaus-Daniel Stachel; Wolfgang Holter; Michael A Kandler; Holger Hertzberg; Wolfgang Rascher; Valentina Campean; Roman Carbon; Holm Schneider
Journal:  Transplantation       Date:  2005-01-27       Impact factor: 4.939

6.  Structure of the human laminin gamma 2 chain gene (LAMC2): alternative splicing with different tissue distribution of two transcripts.

Authors:  T Airenne; H Haakana; K Sainio; T Kallunki; P Kallunki; H Sariola; K Tryggvason
Journal:  Genomics       Date:  1996-02-15       Impact factor: 5.736

7.  Identification of a major heparin and cell binding site in the LG4 module of the laminin alpha 5 chain.

Authors:  P K Nielsen; Y S Gho; M P Hoffman; H Watanabe; M Makino; M Nomizu; Y Yamada
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

8.  Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect.

Authors:  H Morisaki; T Morisaki; L K Newby; E W Holmes
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Herlitz junctional epidermolysis bullosa keratinocytes display heterogeneous defects of nicein/kalinin gene expression.

Authors:  C Baudoin; C Miquel; C Blanchet-Bardon; C Gambini; G Meneguzzi; J P Ortonne
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

10.  Cloning of the beta 3 chain gene (LAMB3) of human laminin 5, a candidate gene in junctional epidermolysis bullosa.

Authors:  L Pulkkinen; D R Gerecke; A M Christiano; D W Wagman; R E Burgeson; J Uitto
Journal:  Genomics       Date:  1995-01-01       Impact factor: 5.736

View more
  10 in total

1.  Early intra-amniotic gene transfer using lentiviral vector improves skin blistering phenotype in a murine model of Herlitz junctional epidermolysis bullosa.

Authors:  M Endo; P W Zoltick; A Radu; Q Jiang; J Qiujie; C Matsui; P M Marinkovich; J McGrath; K Tamai; J Uitto; A W Flake
Journal:  Gene Ther       Date:  2011-09-22       Impact factor: 5.250

2.  Type XVII collagen (BP180) can function as a cell-matrix adhesion molecule via binding to laminin 332.

Authors:  F Van den Bergh; S L Eliason; G J Giudice
Journal:  Matrix Biol       Date:  2010-10-26       Impact factor: 11.583

Review 3.  Laminins: Roles and Utility in Wound Repair.

Authors:  Valentina Iorio; Lee D Troughton; Kevin J Hamill
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-04-01       Impact factor: 4.730

4.  A new mouse model of junctional epidermolysis bullosa: the LAMB3 628G>A knockin mouse.

Authors:  Johanna Hammersen; Jin Hou; Stephanie Wünsche; Sven Brenner; Thomas Winkler; Holm Schneider
Journal:  J Invest Dermatol       Date:  2014-10-28       Impact factor: 8.551

Review 5.  Laminin 332 in junctional epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Cristina Has; Leena Bruckner-Tuderman
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

6.  Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa.

Authors:  Vadim Lincoln; Jon Cogan; Yingping Hou; Michaela Hirsch; Michelle Hao; Vitali Alexeev; Michele De Luca; Laura De Rosa; Johann W Bauer; David T Woodley; Mei Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-26       Impact factor: 11.205

7.  Epidermolysis bullosa in Danish Hereford calves is caused by a deletion in LAMC2 gene.

Authors:  Leonardo Murgiano; Natalie Wiedemar; Vidhya Jagannathan; Louise K Isling; Cord Drögemüller; Jørgen S Agerholm
Journal:  BMC Vet Res       Date:  2015-02-07       Impact factor: 2.741

8.  Targeted next-generation sequencing identifies a novel mutation of LAMB3 in a Chinese neonatal patient presented with junctional epidermolysis bullosa.

Authors:  Hairong Wang; Yun Yang; Jieqiong Zhou; Jiangxia Cao; Xuelian He; Long Li; Shuyang Gao; Bing Mao; Ping Tian; Aifen Zhou
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

9.  Molecular identification of collagen 17a1 as a major genetic modifier of laminin gamma 2 mutation-induced junctional epidermolysis bullosa in mice.

Authors:  Thomas J Sproule; Jason A Bubier; Fiorella C Grandi; Victor Z Sun; Vivek M Philip; Caroline G McPhee; Elisabeth B Adkins; John P Sundberg; Derry C Roopenian
Journal:  PLoS Genet       Date:  2014-02-13       Impact factor: 5.917

10.  Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations.

Authors:  Andrew Kwong; Jon Cogan; Yingping Hou; Richard Antaya; Michelle Hao; Gene Kim; Vadim Lincoln; Qiuyang Chen; David T Woodley; Mei Chen
Journal:  Mol Ther       Date:  2020-03-17       Impact factor: 11.454

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.